EFG International AG Takes $4.57 Million Position in Bristol Myers Squibb Company $BMY

EFG International AG acquired a new position in Bristol Myers Squibb Company (NYSE:BMY) during the second quarter, HoldingsChannel.com reports. The fund acquired 79,256 shares of the biopharmaceutical company’s stock, valued at approximately $4,566,000.

Several other large investors have also added to or reduced their stakes in BMY. Northwestern Mutual Investment Management Company LLC boosted its stake in shares of Bristol Myers Squibb by 0.3% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock worth $3,509,000 after buying an additional 172 shares during the last quarter. KCM Investment Advisors LLC increased its position in shares of Bristol Myers Squibb by 0.8% in the fourth quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock valued at $1,126,000 after acquiring an additional 174 shares during the last quarter. Sandy Cove Advisors LLC increased its position in shares of Bristol Myers Squibb by 4.7% in the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock valued at $227,000 after acquiring an additional 176 shares during the last quarter. Investment Research Partners LLC raised its holdings in Bristol Myers Squibb by 1.4% during the fourth quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock worth $708,000 after acquiring an additional 179 shares in the last quarter. Finally, ESG Planning DBA Harper Investing boosted its position in Bristol Myers Squibb by 1.3% during the fourth quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock valued at $745,000 after purchasing an additional 180 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 0.9%

Shares of BMY opened at $67.86 on Wednesday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The firm has a market cap of $138.62 billion, a P/E ratio of 14.95, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The firm’s 50-day simple moving average is $61.01 and its 200 day simple moving average is $59.54. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same period last year, the business posted $1.46 earnings per share. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts forecast that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.7%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BMY shares. Roth Capital started coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price target for the company. Cantor Fitzgerald reiterated a “neutral” rating and set a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Weiss Ratings raised Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Guggenheim reissued a “buy” rating and issued a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, TD Cowen began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.